Artificial Intelligence-guided Prognostication and Cranial Radiotherapy Optimization in First-line Third-generation EGFR-TKI-treated EGFR-mutant Non-small Cell Lung Cancer With Baseline Brain Metastases: a Multicenter, Observational Study
Latest Information Update: 13 Nov 2024
Price :
$35 *
At a glance
- Drugs Aumolertinib (Primary) ; Firmonertinib (Primary) ; Osimertinib (Primary)
- Indications Brain metastases; Non-small cell lung cancer
- Focus Therapeutic Use
- 11 Nov 2024 Status changed from not yet recruiting to recruiting.
- 30 Sep 2024 New trial record